Gut microbiome may influence sulfasalazine reaction in IBD-SpA
The gut microbiome, the collection of microbes that populate the intestinal tract, could influence the way people with inflammatory bowel disease (IBD) and associated peripheral spondyloarthritis (SpA) respond to sulfasalazine — a medication commonly used to treat IBD that’s also been shown to be effective for SpA. That’s according to…